# A machine-learning method for biobank-scale genetic prediction of blood group antigens

Hyvärinen K<sup>1\*</sup>, Haimila K<sup>2</sup>, Moslemi C<sup>3,4</sup>, Blood Service Biobank<sup>5</sup>, Olsson ML<sup>6,7</sup>, Ostrowski SR<sup>8,9</sup>, Pedersen OB<sup>3,9</sup>, Erikstrup C<sup>10</sup>, Partanen J<sup>1</sup>, Ritari J<sup>1</sup>

- 1. Research and Development, Finnish Red Cross Blood Service, Helsinki, Finland 2. Blood Group Unit, Finnish Red Cross Blood Service, Vantaa, Finland
- 3. Department of Clinical Immunology, Zealand University Hospital, Køge, Denmark
- 4. Department of Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark
  - 5. Finnish Red Cross Blood Service, Vantaa, Finland
  - 6. Department of Laboratory Medicine, Lund University, Lund, Sweden
- 7. Department of Clinical Immunology and Transfusion Medicine, Office for Medical Services, Region Skåne, Sweden
  - 8. Department of Clinical Immunology, Copenhagen University Hospital, Rigshopitalet, Copenhagen, Denmark
  - 9. Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
  - 10. Department of Clinical Immunology, Aarhus University Hospital, Skejby, Denmark

Short title: Blood group prediction method

\*Corresponding author: Kati Hyvärinen, PhD, Associate professor Finnish Red Cross Blood Service **Research and Development** Biomedicum Helsinki 1, Haartmaninkatu 8, 00290 Helsinki, FINLAND Phone +358 40 920 3083 kati.hyvarinen@bloodservice.fi

### 1 ABSTRACT

2 Blood transfusion is a life-saving medical procedure performed routinely worldwide. A key element for successful transfusion is compatibility of the patient and donor red blood cell 3 (RBC) antigens. Precise antigen matching reduces the risk for immunization and other 4 adverse transfusion outcomes. RBC antigens are encoded by specific genes, which allows 5 developing computational methods for determining antigens from genomic data. 6 7 We describe here a classification method for determining RBC antigens from genotyping 8 array data. Random forest models for 39 RBC antigens in 14 blood group systems and for 9 human platelet antigen (HPA)-1 were trained and tested using genotype and RBC antigen 10 and HPA-1 typing data available for 1,192 blood donors in the Finnish Blood Service 11 Biobank. The algorithm and models were further evaluated using a validation cohort of 12 111,667 Danish blood donors. 13 In the Finnish test data set, the median (interguartile range [IQR]) balanced accuracy for 39 models was 99.9 (98.9–100)%. We were able to replicate 34 out of 39 Finnish models in the 14 Danish cohort and the median (IQR) balanced accuracy for classifications was 97.1 (90.1– 15 99.4)%. When applying models trained with the Danish cohort, the median (IQR) balanced 16 17 accuracy for the 40 Danish models in the Danish test data set was 99.3 (95.1–99.8)%. 18 The RBC antigen and HPA-1 prediction models demonstrated high overall accuracies 19 suitable for probabilistic determination of blood groups and HPA-1 at biobank-scale. Furthermore, population-specific training cohort increased the accuracies of the models. 20 This stand-alone and freely available method is applicable for research and screening for 21 22 antigen-negative blood donors. 23 24 25 Keywords 26

27 Red blood cell antigen, blood group, random forest, classification, biobank, blood donor

# 28 INTRODUCTION

29 Blood transfusion is a life-saving procedure performed widely in treating various medical conditions. Despite routine practices, the safety of transfusions remains a major concern<sup>1</sup>. 30 Exposure to foreign RBC antigens may result in alloantibody formation and hemolytic 31 transfusion reactions. Additionally, sensitization to non-self RBC antigens and human 32 platelet antigens (HPAs) can also occur via pregnancy and cause fetal morbidity and 33 34 mortality<sup>2,3</sup>. The current general practice of matching the recipient and blood donor for ABO 35 and RhD antigens is inadequate to prevent sensitization to other antigens. Extended matching could reduce the risk of alloimmunization and adverse events, which are especially 36 pronounced among patients receiving regular transfusions<sup>4,5</sup>. 37

Blood group typing of blood donors has been conventionally performed by serotyping and is 38 still the main method used in blood centers. To overcome limitations regarding low 39 40 throughput and lack of valid reagents for all clinically relevant antigens, numerous DNA-41 based genotyping and sequencing methods have emerged within the last decades<sup>6–10</sup>. This development has been enabled by the accumulating knowledge about the genetic basis of 42 43 the blood groups<sup>11,12</sup> and the rapid evolution of molecular methodology. However, the systematically extended blood group typing of blood donors and, even more so, the 44 recipients, remains sparse. Economic feasibility has been a major restraint to the progress. 45 The development of genotyping array technologies has promoted high-throughput and cost-46 effective genetic studies in many fields and, in 2020, Gleadall et al.<sup>13</sup> introduced a 47 microarray platform for RBC antigen, human leukocyte antigens (HLA), and HPA typing for 48 precision matching of blood. 49

While accurate blood group typing is obligatory for safe transfusions, an initial screening for 50 potential donors could be achieved using less stringent procedures. In the last decade, the 51 52 development of machine learning approaches for high-dimensional data has provided new opportunities for exploitation of expanding genetic data. In 2015, Giollo et al.<sup>14</sup> presented 53 BOOGIE, an RBC antigen predictor based on Boolean rules and k-nearest neighbor (k-NN) 54 algorithm. Decision tree -based methods, including bootstrap aggregation<sup>15</sup> and random 55 forest<sup>16</sup>, have been utilized for imputation of HLA alleles<sup>17,18</sup> and killer cell immunoglobulin-56 like receptor (KIR) copy number<sup>19</sup> and gene content<sup>20</sup>. To our knowledge, these methods 57

have not yet been implemented on RBC antigen and HPA screening. The analysis of high-58 dimensional data with computational performance suitable for large-scale analyses may be 59 implemented using "RANdom forest GEneRator" software R package<sup>21</sup>. The execution is 60 feasible in the local computing environment and sensitive data uploads are not required. 61 62 Here we describe a stand-alone and freely available random forest classification method and models for determining RBC antigens and HPA-1 from array technology-based 63 64 genotyping data. We investigate the performance of models trained with Finnish blood 65 donor biobank data and further validate the method with a Danish cohort. Our results suggest that the method is applicable for biobank-scale probabilistic determination of RBC 66 antigens and HPA-1, and could facilitate research and screening for antigen-negative blood 67 68 donors.

69

#### 70 STUDY SUBJECTS AND METHODS

#### 71 Study cohorts and design

The Finnish study cohort consists of 1,192 blood donors belonging to the Blood Service
Biobank, Helsinki, Finland (https://www.veripalvelu.fi/en/biobank/). Genotype and blood
group phenotype data were obtained from the Blood Service Biobank. The study (biobank
decision 002-2018) conforms to the principles of the Finnish Biobank Act (688/2012) and the
participants have given written informed consent to the Blood Service Biobank.

The Danish validation cohort consists of 111,667 participants of the Danish Blood Donor
Study (DBDS) Genomic Cohort expanding on the Danish blood bank system<sup>22,23</sup>. The genetic
studies in DBDS have been approved by the Danish Data Protection Agency (P-2019-99) and
the Scientific Ethical Committee system (NVK-1700407).

81

# 82 *Genotyping and genotype imputation*

83 The genotyping and genotype imputation of the Finnish cohort have been performed

84 originally as a part of FinnGen project (<u>https://www.finngen.fi/en</u>). Biobank samples were

85 genotyped using FinnGen ThermoFisher Axiom custom array v2 (Thermo Fisher Scientific,

- 86 Santa Clara, CA, USA) and imputed using the population-specific Sisu v3 imputation
- 87 reference panel with Beagle 4.1. Detailed description of the procedures is available at
- 88 https://finngen.gitbook.io/documentation/v/r4/methods/genotype-imputation and the
- 89 marker content of the custom array v2 is downloadable at
- 90 <u>https://www.finngen.fi/en/researchers/genotyping</u>. The phased genotypes were filtered for
- 91 the imputation INFO-score >0.6 and were in vcf format.
- 92 In the Danish cohort, the genotyping was performed using Illumina's Infinium Global
- 93 Screening Array and imputed using the deCODE genetics' (Reykjavik, Iceland) North
- 94 European reference sequence panel. Unphased genotypes were filtered for the imputation
- 95 INFO-score >0.75, minor allele frequency >0.01, Hardy–Weinberg equilibrium P-values <1
- 96  $\times 10^{-4}$ , and samples for missingness per individual <3%.
- 97

# 98 RBC antigen and HPA typing

- 99 The RBC antigen and HPA-1 phenotypic information for the Finnish and Danish cohorts is
- presented in **Table 1**. The availability of the phenotype data varied in a wide range
- 101 depending on the antigen due to the different testing criteria practices. In the Finnish
- 102 cohort, RBC antigen and HPA-1 typing was performed at the FRCBS Blood Group Unit by
- routine methods and the results were obtained using validated serological and genotypingtechniques.
- 105 The sources for RBC antigen and HPA-1 typing results were the Danish electronic blood bank
- systems and the typing was performed using serological methods, except for Vel-status,
- 107 which was determined using polymerase chain reaction technique.
- 108

#### 109 Classification random forest models

- 110 An overview of the study design is depicted in **Figure 1**. RBC antigen and HPA-1 coding genes
- and the genetic regions used in the models are presented in **Supplementary Table 1**. The
- models for the antigens were generated separately using the same hyperparameters. Only
- antigens having at least four cases in each respective typing data class were included,
- resulting altogether in 39 models. For the Finnish reference data set, SNVs in RBC antigen

and HPA-1 coding genetic regions ± 2,000 bp flanking regions were utilized in dosage
format. **Table 2** presents the number of SNVs available for each model. Only samples having
full dosage data were used. The genetic and antigen typing information were combined into
a single full data set and divided randomly 1:1 into train and test data sets.

R v4.3.0 environment<sup>24</sup> was used for the implementation and classification random forest 119 models were created using the R package ranger v0.13.1<sup>21</sup>. The number of trees was 2,000 120 121 and split criteria based on node impurity measured by the Gini index. Class weights were 122 applied due to unbalanced outcome classes. Number of variables to possibly split at each node (mtry) was number of SNVs divided by 2 and the variable importance was determined 123 by permutation. Feature selection was based on variable importance >0 and the model was 124 re-fitted using these important SNVs only. The number of important variables and 125 prediction errors for each antigen model are presented in the Table 2. Prediction error was 126 determined as misclassification frequency obtained from out-of-bag data and prediction on 127 the test set. The important variables for Finnish models are listed in **Supplementary Data 2**. 128 129 The full data set was used in fitting the final models.

130

#### 131 Model evaluation metrics

132 The model accuracy was evaluated using sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and balanced accuracy. The data was wrangled using 133 tidyverse v1.3.1 package<sup>25</sup> and the evaluation metrics were derived using caret v6.0- $92^{26}$ . 134 For each model, the number of true positives (TP), true negatives (TN), false positives (FP) 135 and false negatives (FN) were determined. Sensitivity was defined as TP / (TP + FN), 136 specificity as TN / (TN + FP), PPV as TP / (TP + FP), NPV as TN / (TN + FN)<sup>27</sup>. Balanced 137 138 accuracy accounts for imbalanced classification and was defined as (sensitivity + specificity) / 2. 139

140

141 Validation of the Finnish models and the random forest method for generating the models

142 The models obtained using the Finnish data set were applied to the Danish cohort. The

implementation required imputed genotype data in vcf or PLINK format. The Danish allele

dosage data was harmonized by naming and allele orientation for compatibility with the
Finnish models and the dosage data for the missing important variables was imputed using
mean values.

147 The model-generating method was further validated by fitting the models on the Danish

148 data set to create models specific to the Danish cohort. In the Danish data set, the

149 percentage of missing genotypes was on average 5% depending on the genetic region of the

150 blood group/HPA system. Missing allele dosage values were imputed separately for train

and test data sets using mean values before classification random forest step.

152 Characteristics of the Danish models are presented in **Supplementary Table 2**. The

153 important variables for the Danish models are listed in **Supplementary Data 3**. The

154 evaluation metrics for both prediction and modelling were defined as depicted in the

155 *"Model evaluation metrics"* section.

156 The significance of variation of balanced accuracies was analyzed using Mann-Whitney-

157 Wilcoxon Test implemented with R v3.6.1.

158

# 159 Data availability

160 Genotyping and RBC antigen/phenotype and HPA-1 typing data for the Finnish cohort are

161 stored in the Blood Service Biobank, Helsinki, Finland. Researchers may apply for access to

162 data (<u>https://www.veripalvelu.fi/en/biobank/for-researchers/</u>). Due to privacy laws, the

Danish genetic data and phenotypes are only available to DBDS researchers and bloodbanks.

165

# 166 **RESULTS**

### 167 Evaluation of the Finnish classification models

In the Finnish cohort, the genotype data was accessible for 1,192 blood donors and the RBC
antigen typing data was available for 39 antigens representing 15 blood group systems. The
blood group typing frequency varied greatly depending on RBC antigen/phenotype, being at
the lowest 5% for HPA-1b and at the highest 100% for A, B, AB, O, K, D, C, c, E, and e (Table
172 1).

- After data partitioning, the number of study subjects in the test data set was 596. The
- median (interquartile range [IQR]) balanced accuracy for 39 models was 99.9 (98.9–100)% in
- the test data set and accuracy metrics for all models are presented in the Table 3. The
- models for antigen/phenotype positivity of AB, B, A<sub>1</sub>, A<sub>2</sub>, Yt<sup>b</sup>, Co<sup>a</sup>, Do<sup>a</sup>, Do<sup>b</sup>, Fy<sup>a</sup>, HPA-1b, K,
- 177 Kp<sup>a</sup>, Ul<sup>a</sup>, Jk<sup>a</sup>, Lu<sup>a</sup>, S, and s reached balanced accuracy of 100%. For other models, the
- 178 balanced accuracy was ≥98.0%, except 83.3% for Ls<sup>a</sup>, 94.0% for Le<sup>b</sup>, 95.0% for HPA-1a, and
- 179 96.0% for hr<sup>s</sup>. Accuracy metrics for the test and full data sets are presented in the
- 180 Supplementary Tables 3 and 4, respectively. Figure 2 illustrates the confusion matrices for
- 181 classification models in the Finnish test data set. The number of false negative plus false
- positive (FN + FP) samples out of all samples was low, ranging from 0 to 1% in all models,
- 183 except 2% for hr<sup>s</sup>. Confusion matrices for the test and full data sets are presented in
- 184 Supplementary Figures 1 and 2, respectively. The median (IQR) prediction error,
- determined as misclassification frequency obtained from out-of-bag data, of the Finnish
- 186 models was  $1.6 \times 10^{-3} (1.9 \times 10^{-4} 7.0 \times 10^{-3})$  (**Table 2.**).

The distributions of posterior probabilities (PP) in the test data set are depicted in Figure 3. 187 The samples having PP >0.5 were classified as antigen positive and  $\leq 0.5$  as antigen negative. 188 The majority of the PPs were close to 1 for the antigen typing positive samples and close to 189 0 for the antigen typing negative samples. The Co<sup>a</sup>-negative samples (only two samples in 190 191 the test data set) were classified correctly but the PPs were closer to 0.5 than to 0. One of the three Ls<sup>a</sup>-positive samples were misclassified and the PPs for the other two were closer 192 to 0.5 than to 1 (specificity 66.7%). The spectrum of PP distribution with some 193 misclassifications was observed for Co<sup>b</sup>, Le<sup>b</sup>, M, N, C, C<sup>w</sup>, D, and hr<sup>S</sup>. Supplementary Figures 194

195 **3** and **4** depict the distributions of PPs in the test and full data sets.

#### 196

# 197 Validation of the Finnish classification models in the Danish cohort

The Danish validation cohort had genotype and phenotype data for 34 out of the 39 Finnish classification models. Antigen/phenotype typing data varied from 433 for A<sub>2</sub> to ~111,000 for A, AB, B, O, and D (**Table 1**). Due to missing Finnish model variables in the Danish genotype data, the Danish allele dosage data was harmonized using mean imputation before applying the Finnish models.

- The median (IQR) balanced accuracy for classifications was 97.1 (90.1–99.4)% and all the
- 204 evaluation metrics are presented in **Supplementary Table 4**. The balanced accuracies were
- 205 >98.0% for 14 models including antigen/phenotype positivity of A, AB, B, O, Yt<sup>b</sup>, Do<sup>a</sup>, Do<sup>b</sup>,
- 206 HPA-1a, Jk<sup>a</sup>, Le<sup>a</sup>, S, s, E, and e. Models for antigen/phenotype positivity of A<sub>1</sub>, Co<sup>b</sup>, Fy<sup>a</sup>, Fy<sup>b</sup>,
- 207 HPA-1b, K, Kp<sup>a</sup>, Lu<sup>a</sup>, M, N, and C<sup>w</sup> had balanced accuracy ranging from 91.6 to 98.0%. Six
- 208 models, A<sub>2</sub>, Co<sup>a</sup>, Jk<sup>b</sup>, Le<sup>b</sup>, D, and C had balanced accuracy ranging from 64.6 to 89.4%. The
- 209 Finnish models for LW<sup>b</sup>, P1, and c failed classification in the Danish cohort.
- 210

# 211 Validation of the classification model algorithm in the Danish cohort

The RBC antigen/phenotype and HPA-1 typing and genotype data available for the Danish cohort enabled implementation of 40 Danish classification models representing 15 blood group systems. Due to missing genotypes (approximately 5%), missing allele dosage values were imputed separately for train and test data sets using mean values.

- 216 Median (IQR) balanced accuracy for the 40 Danish models in the Danish test data set was 217 99.3 (95.1–99.8)%. The evaluation metrics for test data set are available in Table 4 and for the train and full data sets in Supplementary Tables 6-7, respectively. Majority (23/40) of 218 the Danish models reached balanced accuracy of ≥99.0% including models for 219 antigen/phenotype positivity of A, AB, B, O, Yt<sup>a</sup>, Yt<sup>b</sup>, Do<sup>a</sup>, Do<sup>b</sup>, Fy<sup>a</sup>, HPA-1a, HPA-1b, Jk<sup>a</sup>, Jk<sup>b</sup>, 220 M, N, S, s, C, c, D, E, Le<sup>a</sup>, and Kn<sup>b</sup>. Balanced accuracies for A<sub>1</sub>, Co<sup>b</sup>, Fy<sup>b</sup>, K, Kp<sup>a</sup>, Lu<sup>a</sup>, C<sup>w</sup>, e, and 221 P1 models ranged from 94.4 to 98.1%, and for A<sub>2</sub>, Co<sup>a</sup>, k, Kp<sup>b</sup>, Lu<sup>b</sup>, Vel, and Le<sup>b</sup> from 70.0 to 222 89.3%. Danish model for Kn<sup>a</sup> failed classification due to too low number of Kn<sup>a</sup>-negative 223
- samples in the test data set. Confusion matrices for the Danish models in the Danish train,

- test and full data sets depict the distribution of TN, FN, TP, and FP samples and are
- illustrated in Supplementary Figures 5–7, respectively. The median (IQR) prediction error of
- the Danish models was  $2.3 \times 10^{-3}$  (9.3 x  $10^{-4}$  7.1 x  $10^{-3}$ )% (Supplementary Table 5).
- 228

# 229 Comparison of the Finnish and Danish classification models

- Assembly of the balanced accuracies for Finnish and Danish models in the Finnish and
- 231 Danish full data sets is presented in **Table 5**. When analyzing the shared 33 models, the
- 232 Finnish models predicted the blood groups of the Finnish cohort more accurately than the
- blood groups of the Danish cohort (median [IQR] balanced accuracy 99.9 [98.8–100]% vs.
- 97.1 [91.6–99.5], p = 1.15e-06). The Danish models were performing better than the Finnish
- models in the blood group classification of the Danish cohort (median [IQR] balanced
- 236 accuracy 99.5 [96.5–99.8]% vs. 97.1 [91.6–99.5]%, p = 0.006).
- 237 The number of genetic variants available for the Finnish random forest modelling ranged
- from 35 to 688 depending on the blood group/HPA system and number of the important
- variables selected by the classifier for the final models ranged from 12 to 214 (**Table 2**). In
- the Danish genotyping data set, the number of variants varied from 42 to 766 and the final
- 241 models utilized 20–743 variants (Supplementary Table 5).

242

243

244

### 245 **DISCUSSION**

246 Our study introduces random forest classification models for predicting RBC

247 antigens/phenotypes and HPA-1 from array-based genotyping data. The method and

248 models were generated utilizing blood group typing data from Finnish blood donors and

249 further validated using a large Danish blood donor cohort. The results demonstrate high

250 overall accuracy, and the method is suitable for biobank-scale screening and analysis of

251 HPA-1 and RBC antigens.

252 Blood transfusion is one of the most common clinical procedures in the hospitals and the

key element for safe transfusion is compatibility between the recipient and donor RBC

antigens<sup>1</sup>. Although transfusion-related severe outcomes are rare, the prominent risk of

255 sensitization and further alloimmunization affects especially patients dependent on

recurrent transfusions <sup>4,5</sup>. Extended blood group typing has proven to be beneficial by

reducing the incidence of alloantibody formation<sup>28,29</sup>. Additionally, studies have shown that

the extended genotyping of blood donors markedly increases the number of suitable donors

for immunized recipients <sup>13</sup> and enhances the supply of antigen-negative blood<sup>6</sup>.

260 At present, preventive matching strategies are implemented only for specific patient groups 261 and, despite the obvious advantages of the extended genotyping of donors, the procedure 262 has not been considered feasible covering all blood donors. Over the last decades, the 263 genotyping of different populations has expanded widely. Using machine learning approaches to screen blood donor and research biobank genotyping data may provide a 264 cost-effective solution for enlarging the pool of antigen-negative blood donors. Our random 265 forest classification method infers RBC antigens and HPA-1 from genotype-imputed 266 microarray data. The R package ranger performed fast and handled the dimensionality of 267 input data without problems<sup>21</sup>. The obtained results demonstrated high balanced accuracies 268 269 both in the Finnish discovery cohort (median 99.8% for the 39 Finnish models) and in the 270 Danish validation cohort (median 99.3% for the 40 Danish models) (Table 5). The performance was not affected by nearly a 100-fold size difference between the Finnish and 271 the Danish cohorts (~1,200 vs. ~111,000, respectively). 272

273 Rh and MNS blood group system antigens have been challenging to determine by
274 sequencing due to complex genetic variation and gene rearrangements<sup>12,30</sup>. We observed

reduced balanced accuracy in the Finnish model for hr<sup>S</sup> (93.3%) and the Danish model for C<sup>w</sup>
(95.3%). However, the other Rh and MNS antigen models, including clinically significant E, e,
C, c, S, and s, performed accurately. The balanced accuracies for clinically significant
antigens in other systems, including K, Jk<sup>a</sup>, Jk<sup>b</sup>, Fy<sup>a</sup>, and Fy<sup>b</sup>, ranged from 95.6% to 100%
(Table 5).

The BOOGIE method for prediction of RBC antigens was published in 2015<sup>14</sup>. It builds on 1-280 281 NN algorithm and implementation requires genotype sequencing data and curated 282 haplotype tables for the RBC antigen phenotypes. When compared, the Finnish models for ABO and RhD performed better than the BOOGIE method (median balanced accuracy for 283 the Finnish ABO models 100% vs. BOOGIE ABO accuracy 94.2%; balanced accuracy for the 284 Finnish RhD model 98.8% vs. BOOGIE RhD accuracy 94.2%). The observed differences in 285 accuracies could be explained by the potentially limited haplotype tables utilized by 286 BOOGIE. Additionally, the reported results of BOOGIE are based on low number of samples. 287

288 When applying the Finnish models to the Danish cohort, the observed decrease in balanced accuracies was expected because of the evident genetic, genotyping, and imputation 289 290 differences between the Finnish and the Danish cohorts (Table 5). The Finnish cohort was imputed using population-specific imputation reference panel having no missingness per 291 292 individual. On the contrary, the Danish cohort was imputed using the North European reference sequence panel resulting in an average missingness of 5%. As random forest is not 293 294 able to handle missing input data and the important variables of the Finnish models were not fully present in the Danish data, we were obliged to use mean imputation for missing 295 variant dosage data. It is obvious that this approach also introduces errors to the data, 296 297 which may partly explain the reduced accuracy. The better performance of the Danish models in Danish cohort underlined the benefit of the population-specific training cohort. 298

To our surprise, the Finnish genotyping data had only one variant in the *RHD* region.
Nonetheless, the Finnish model for RhD performed with sufficient balanced accuracy in the
Finnish cohort (98.8%). Our method combines *RHD* and *RHCE* region variants for the
modelling and the high linkage disequilibrium may have supported the classification (**Table**However, the Finnish model for RhD worked poorly in the Danish cohort (78.4%), which
may be attributed to the mean imputation of missing values.

The present modelling method is restricted to the RBC antigen typing data available for the
training and test data sets, which can be considered as a major limitation because the data
for some RBC antigens are scarce. RBC antigens have demonstrated significant diversity
among populations and rare blood group variants may not be discovered without
substantially large typing numbers. The Danish model for Kn<sup>a</sup> failed because of lacking Kn<sup>a</sup>negative samples in the test data set and we were not able to create Finnish models for e.g.,
Vel, k, Kp<sup>b</sup>, Lu<sup>a</sup>, and LW<sup>a</sup>.

In the future, comprehensive donor and recipient typing and precision matching are likely to increase. A recent publication by van Sambeeck *et al.*<sup>31</sup> demonstrated the feasibility of preventive matching for all genotyped recipients and donors. Our method is suitable for initial screening for antigen-negative donors at biobank-scale, presenting a cost-effective solution for the extended blood group and HPA-1 typing. Additionally, successful prediction of polygenic blood groups may facilitate the research of desease associations in large biobanks.

319 Scripts for random forest modelling and for applying the tested 39 Finnish models are freely 320 available in the GitHub. The implementation is possible in the local computing environment 321 without sensitive data uploads and requires only a moderate level of bioinformatic skills.

322

#### 323 AUTHOR CONTRIBUTION

324 K. Hyvärinen, K. Haimila, J. Partanen, and J. Ritari designed the study. The Blood Service Biobank provided the samples and genomic data. K. Haimila supervised blood group typing 325 and provided blood group expertise. K. Hyvärinen and J. Ritari scripted the random forest 326 327 method, carried the analyses out in the Finnish cohort, and interpret the results. O.B. Pedersen and C. Erikstrup established the Danish cohort. C. Moslemi executed the 328 replications analysis in the Danish cohort. M.L. Olsson, S.R. Ostrowski. and O.B. Pedersen 329 supervised and interpreted the analysis performed in the Danish cohort. K. Hyvärinen 330 331 drafted the manuscript. All authors contributed to the final version of the manuscript.

332

#### 333 ACKNOWLEDGEMENTS

We want to thank Dr. Satu Pastila and Ms. Ritva Toivanen at the FRCBS for the collaboration
with the blood group typing data. We are also grateful for Ms. Birgitta Rantala, Mr. Petteri
Vaskin, Ms. Katariina Karjalainen, Ms. Nina Nikiforow, Ms. Jonna Clancy, and Dr. Mikko
Arvas and Dr. Tiina Wahlfors at the Blood Service Biobank for their help in handling the data
and samples, and Dr. Jaana Mättö and the personnel at the FRCBS Blood Group Unit for
blood group typing analyses.

From Denmark, we wish to thank the Danish blood donors and deCODE Genetics forgenotyping the Danish cohort.

342

# 343 DISCLOSURE AND FUNDING

- 344 M.L. Olsson is an inventor on patents about Vel blood group genotyping (unrelated to the
- 345 methods and models presented in this study) and owns 50% each of the shares in BLUsang
- AB, an incorporated consulting firm, which receives royalties for said patents. The other
- 347 authors declare no conflicts of interest.
- 348 The study was partially supported by funding from the Government of Finland VTR funding,
- 349 the Academy of Finland, the Finnish Cancer Association, and Business Finland. The study of
- 350 the Danish cohort was supported by Independent Research Fund Denmark (project number
- 0214-00127B), Bloddonornes forskningsfond, and A.P Møller Fonden. M.L. Olsson is a
- 352 Wallenberg Clinical Scholar funded by Knut and Alice Wallenberg Foundation.

353

# 354 SUPPORTING INFORMATION STATEMENT

355 Supplementary Information is online.

# REFERENCES

- Goel R, Tobian AAR, Shaz BH. Noninfectious transfusion-associated adverse events and their mitigation strategies. *Blood*. 2019;133(17):1831-1839. doi:10.1182/blood-2018-10-833988
- Hendrickson JE, Delaney M. Hemolytic Disease of the Fetus and Newborn: Modern Practice and Future Investigations. *Transfus Med Rev.* 2016;30(4):159-164. doi:10.1016/j.tmrv.2016.05.008
- Bussel JB, Vander Haar EL, Berkowitz RL. New developments in fetal and neonatal alloimmune thrombocytopenia. *Am J Obstet Gynecol*. 2021;225(2):120-127. doi:10.1016/j.ajog.2021.04.211
- 4. Hendrickson JE, Tormey CA, Shaz BH. Red blood cell alloimmunization mitigation strategies. *Transfus Med Rev.* 2014;28(3):137-144. doi:10.1016/j.tmrv.2014.04.008
- Evers D, Middelburg RA, de Haas M, et al. Red-blood-cell alloimmunisation in relation to antigens' exposure and their immunogenicity: a cohort study. *Lancet Haematol*. 2016;3(6):e284-e292. doi:10.1016/S2352-3026(16)30019-9
- 6. Flegel WA, Gottschall JL, Denomme GA. Implementing mass-scale red cell genotyping at a blood center. *Transfusion*. 2015;55(11):2610-2615. doi:10.1111/trf.13168
- Cone Sullivan JK, Gleadall N, Lane WJ. Blood Group Genotyping. *Clin Lab Med*.
   2022;42(4):645-668. doi:10.1016/J.CLL.2022.09.016
- Lane WJ, Westhoff CM, Gleadall NS, et al. Automated typing of red blood cell and platelet antigens: a whole-genome sequencing study. *Lancet Haematol*. 2018;5(6):e241-e251. doi:10.1016/S2352-3026(18)30053-X
- Veldhuisen B, Van Der Schoot CE, De Haas M. Blood group genotyping: From patient to high-throughput donor screening. *Vox Sang*. 2009;97(3):198-206. doi:10.1111/j.1423-0410.2009.01209.x
- Hyun J, Oh S, Hong YJ, Park KU. Prediction of various blood group systems using Korean whole-genome sequencing data. *PLoS One*. 2022;17(6). doi:10.1371/JOURNAL.PONE.0269481

- Möller M, Jöud M, Storry JR, Olsson ML. Erythrogene: a database for in-depth analysis of the extensive variation in 36 blood group systems in the 1000 Genomes Project. *Blood Adv.* 2016;1(3):240-249. doi:10.1182/bloodadvances.2016001867
- 12. ISBT Blood Group Allele Tables. https://www.isbtweb.org/isbt-workingparties/rcibgt/blood-group-allele-tables.html#blood group allele tables
- Gleadall NS, Veldhuisen B, Gollub J, et al. Development and validation of a universal blood donor genotyping platform: A multinational prospective study. *Blood Adv*. 2020;4(15):3495-3506. doi:10.1182/bloodadvances.2020001894
- Giollo M, Minervini G, Scalzotto M, Leonardi E, Ferrari C, Tosatto SCE. BOOGIE: Predicting blood groups from high throughput sequencing data. *PLoS One*. 2015;10(4):1-15. doi:10.1371/journal.pone.0124579
- 15. Breiman L. Bagging predictors. *Mach Learn*. 1996;26(2):123-140.
- Breiman L. Random forests. *Mach Learn*. 2001;45(1):5-32.
   doi:10.1023/A:1010933404324/METRICS
- 17. Zheng X, Shen J, Cox C, et al. HIBAG—HLA genotype imputation with attribute bagging. *Pharmacogenomics J*. 2014;14(2):192-200. doi:10.1038/tpj.2013.18
- Ritari J, Hyvärinen K, Clancy J, FinnGen, Partanen J, Koskela S. Increasing accuracy of HLA imputation by a population-specific reference panel in a FinnGen biobank cohort. NAR Genomics Bioinforma. 2020;2(2):lqaa030. doi:10.1093/nargab/lqaa030
- 19. Vukcevic D, Traherne JA, Næss S, et al. Imputation of KIR Types from SNP Variation Data. *Am J Hum Genet*. 2015;97(4):593-607. doi:10.1016/j.ajhg.2015.09.005
- Ritari J, Hyvärinen K, Partanen J, Koskela S. KIR gene content imputation from singlenucleotide polymorphisms in the Finnish population. *PeerJ*. 2022;10(e12692). doi:10.7717/peerj.12692
- Wright MN, Ziegler A. ranger: A Fast Implementation of Random Forests for High Dimensional Data in C++ and R. J Stat Softw. 2017;77(1):1–17. doi:10.18637/jss.v077.i01

- Pedersen OB, Erikstrup C, Kotzé SR, et al. The Danish Blood Donor Study: A large, prospective cohort and biobank for medical research. *Vox Sang*. 2012;102(3):271. doi:10.1111/j.1423-0410.2011.01553.x
- Hansen TF, Banasik K, Erikstrup C, et al. DBDS Genomic Cohort, a prospective and comprehensive resource for integrative and temporal analysis of genetic, environmental and lifestyle factors affecting health of blood donors. *BMJ Open*. 2019;9(6). doi:10.1136/bmjopen-2018-028401
- 24. R Core Team. *R: A Language and Environment for Statistical Computing*. R Foundation for Statistical Computing; 2023. https://www.r-project.org/
- 25. Wickham H, Averick M, Bryan J, et al. Welcome to the Tidyverse. J Open Source Softw.
  2019;4(43):1686. doi:10.21105/joss.01686
- 26. Kuhn M. Building Predictive Models in R Using the caret Package. J Stat Softw.
  2008;28(5):1–26. doi:10.18637/jss.v028.i05
- Monaghan TF, Rahman SN, Agudelo CW, et al. Foundational Statistical Principles in Medical Research: Sensitivity, Specificity, Positive Predictive Value, and Negative Predictive Value. *Medicina (Kaunas)*. 2021;57(5). doi:10.3390/medicina57050503
- Lasalle-Williams M, Nuss R, Le T, et al. Extended red blood cell antigen matching for transfusions in sickle cell disease: a review of a 14-year experience from a single center (CME). *Transfusion*. 2011;51(8):1732-1739. doi:10.1111/J.1537-2995.2010.03045.X
- Schonewille H, Honohan Á, Van Der Watering LMG, et al. Incidence of alloantibody formation after ABO-D or extended matched red blood cell transfusions: a randomized trial (MATCH study). *Transfusion*. 2016;56(2):311-320. doi:10.1111/TRF.13347
- Zhang Z, An HH, Vege S, et al. Accurate long-read sequencing allows assembly of the duplicated RHD and RHCE genes harboring variants relevant to blood transfusion. *Am J Hum Genet*. 2022;109(1):180-191. doi:10.1016/j.ajhg.2021.12.003
- 31. van Sambeeck JHJ, van der Schoot CE, van Dijk NM, Schonewille H, Janssen MP.

Extended red blood cell matching for all transfusion recipients is feasible. *Transfus Med*. 2022;32(3):221-228. doi:10.1111/TME.12831

# **FIGURE LEGENDS**

**Figure 1. Study design.** Random forest classification models were generated using Finnish reference data set (n = 1,192). Allele dosages of genes determining RBC antigens/phenotypes and HPA-1 were combined with the antigen typing data. The dataset was divided randomly to train and test data sets. Random forest modelling was executed in the training data set (n = 596) and the important variables were selected using permutation. The models were evaluated in the test data set (n = 596) for prediction accuracy and errors. The final models were fitted using the full data set and both models and the method were validated in the Danish cohort (n = 111,677).

**Figure 2.** Confusion matrices of the Finnish models in the Finnish test data set. Confusion matrices for the Finnish antigen classification models in the Finnish test data set are presented in alphabetical order of the blood group systems. The RBC antigen/phenotype and HPA-1 typing results are on the x-axis and the model predictions on the y-axis. The antigen-negative samples are denoted by 0 and the antigen-positive samples by 1 on both axes. The numbers of true positive and true negative samples are depicted in the green boxes and the numbers of false positive and false negative samples in the red boxes.

# Figure 3. Posterior probability boxplots of the Finnish models in the Finnish test data set.

Posterior probability boxplots for the Finnish antigen classification models in the Finnish test data set are presented in alphabetical order of the blood group systems. The RBC antigen/phenotype and HPA-1 typing results are on the x-axis and the antigen-negative samples are denoted by 0 and the antigen-positive samples by 1. The posterior probabilities for samples range from 0 to 1 and are presented on the y-axis. Samples are depicted as open circles.

# Table 1. Blood group/HPA-1 antigen typing information of the Finnish and Danish cohorts.

| Blood group/HPA<br>system | Antigen <sup>a</sup> | Finnish<br>cohort(n) | Antigen<br>positivity in the<br>Finnish<br>cohort(%) | Danish cohort(n) | Antigen<br>positivity in the<br>Danish<br>cohort(%) |
|---------------------------|----------------------|----------------------|--|------------------|---|
| ABO                       | А                    | 1,192                | 40.9   | 111,656          | 41.2  |
| ABO                       | A <sub>1</sub>       | 70                   | 62.9   | 17,541           | 75.3  |
| ABO                       | A <sub>2</sub>       | 70                   | 38.6   | 433              | 27.0  |
| ABO                       | AB                   | 1,192                | 8.0  | 111,656          | 4.4   |
| ABO                       | В                    | 1,192                | 8.2  | 111,656          | 10.2  |
| ABO                       | 0                    | 1,192                | 42.9   | 111,656          | 44.2  |
| Cartwright                | Yt <sup>a</sup>      | NA                   | NA   | 7,640            | 99.6  |
| Cartwright                | Yt <sup>b</sup>      | 1,160                | 6.2  | 7,362            | 7.3   |
| Colton                    | Co <sup>a</sup>      | 1,162                | 99.8   | 7,490            | 98.5  |
| Colton                    | Co <sup>b</sup>      | 1,164                | 7.3  | 8,277            | 9.2   |
| Dombrock                  | Do <sup>a</sup>      | 1,162                | 53.1   | 7,352            | 62.9  |
| Dombrock                  | Do <sup>b</sup>      | 1,162                | 90.7   | 7,352            | 84.6  |
| Duffy                     | Fy <sup>a</sup>      | 1,177                | 67.0   | 77,920           | 67.0  |
| Duffy                     | Fy <sup>b</sup>      | 1,175                | 75.1   | 71,096           | 80.8  |
| Gerbich                   | Ls <sup>a</sup>      | 190                  | 3.2  | NA               | NA  |
| HPA-1                     | HPA-1a               | 232                  | 91.4   | 518              | 97.1  |
| HPA-1                     | HPA-1b               | 62                   | 43.5   | 518              | 30.7  |
| Kell                      | К                    | 1,192                | 4.7  | 96,497           | 7.8   |
| Kell                      | k                    | NA                   | NA   | 14,332           | 99.0  |
| Kell                      | Kp <sup>a</sup>      | 1,177                | 2.6  | 22,497           | 2.4   |
| Kell                      | Крь                  | NA                   | NA   | 10,350           | 99.9  |
| Kell                      | Ula                  | 219                  | 15.5   | NA               | NA  |
| Kidd                      | Jk <sup>a</sup>      | 1,177                | 72.6   | 77,986           | 76.6  |
| Kidd                      | Jk <sup>b</sup>      | 1,177                | 68.5   | 71,840           | 72.7  |
| Knops                     | Knª                  | NA                   | NA   | 3,462            | 99.9  |
| Knops                     | Kn <sup>b</sup>      | NA                   | NA   | 3,462            | 6.8   |
| Landsteiner-Wiener        | LW <sup>b</sup>      | 327                  | 5.2  | NA               | NA  |
| Lewis                     | Le <sup>a</sup>      | 253                  | 10.2   | 9,220            | 17.4  |
| Lewis                     | Le <sup>b</sup>      | 253                  | 80.2   | 8,925            | 56.5  |
| Lutheran                  | Lu <sup>a</sup>      | 1,164                | 3.6  | 9,615            | 8.6   |
| MNS                       | М                    | 1,177                | 87.7   | 29,642           | 78.1  |
| MNS                       | Ν                    | 1,177                | 59.0   | 14,837           | 71.6  |
| MNS                       | S                    | 1,177                | 54.2   | 28,949           | 50.4  |
| MNS                       | S                    | 1,177                | 87.6   | 24,291           | 90.9  |
| P1PK                      | P1                   | 253                  | 75.9   | 7,465            | 77.4  |
| Rh                        | С                    | 1,192                | 54.4   | 44,451           | 63.3  |
| Rh                        | с                    | 1,192                | 79.4   | 42,968           | 82.2  |
| Rh                        | Cw                   | 1,177                | 3.2  | 40,720           | 3.3   |
| Rh                        | C×                   | 337                  | 12.2   | NA               | NA  |
| Rh                        | D                    | 1,192                | 71.6   | 111,667          | 79.5  |
| Rh                        | E                    | 1,192                | 19.9   | 89,289           | 28.1  |
| Rh                        | e                    | 1,192                | 96.2   | 82,467           | 97.3  |

| Rh  | hr <sup>B</sup> | 1,162 | 96.4 | NA     | NA   |
|-----|-----------------|-------|------|--------|------|
| Rh  | hr <sup>s</sup> | 1,162 | 97.3 | NA     | NA   |
| Vel | Vel             | NA    | NA   | 11,755 | 99.9 |

NA, data not available.

 $^{\rm a}$  O, A1, and A2 and in this column refer to phenotype.

| Blood group/HPA<br>system | Antigenª        | Genes analyzed      | n(variants<br>available) | n(model variants) | Prediction error <sup>b</sup> |
|---------------------------|-----------------|---------------------|--------------------------|-------------------|-------------------------------|
| ABO                       | ABO             | ABO                 | 496                      | 164               | 8.68E-04                      |
| ABO                       | A <sub>1</sub>  | ABO                 | 496                      | 18                | 1.29E-03                      |
| ABO                       | A <sub>2</sub>  | ABO                 | 496                      | 43                | 2.20E-02                      |
| Cartwright                | Yt <sup>b</sup> | ACHE                | 62                       | 12                | 0.00E+00                      |
| Colton                    | Coa             | AQP1                | 108                      | 15                | 4.26E-04                      |
| Colton                    | Co <sup>b</sup> | AQP1                | 108                      | 39                | 2.03E-03                      |
| Dombrock                  | Do <sup>a</sup> | ART4                | 109                      | 17                | 6.97E-05                      |
| Dombrock                  | Do <sup>b</sup> | ART4                | 109                      | 17                | 0.00E+00                      |
| Duffy                     | Fy <sup>a</sup> | ACKR1               | 57                       | 25                | 6.80E-05                      |
| Duffy                     | Fy <sup>b</sup> | ACKR1               | 57                       | 26                | 4.32E-03                      |
| Gerbich                   | Ls <sup>a</sup> | GYPC                | 342                      | 81                | 7.71E-03                      |
| HPA-1                     | HPA-1a          | ITGB3               | 386                      | 24                | 1.74E-03                      |
| HPA-1                     | HPA-1b          | ITGB3               | 386                      | 73                | 2.06E-02                      |
| Kell                      | К               | KEL                 | 127                      | 33                | 2.93E-05                      |
| Kell                      | Kp <sup>a</sup> | KEL                 | 127                      | 26                | 8.56E-05                      |
| Kell                      | Ula             | KEL                 | 127                      | 21                | 2.01E-04                      |
| Kidd                      | Jka             | SLC14A1             | 622                      | 18                | 1.62E-04                      |
| Kidd                      | Jkp             | SLC14A1             | 622                      | 178               | 8.14E-04                      |
| Landsteiner-Wiener        | Lw <sup>b</sup> | ICAM4               | 35                       | 19                | 4.27E-03                      |
| Lewis                     | Le <sup>a</sup> | FUT2, FUT3          | 199                      | 45                | 4.13E-03                      |
| Lewis                     | Le <sup>b</sup> | FUT2, FUT3          | 199                      | 88                | 1.56E-02                      |
| Lutheran                  | Lu <sup>a</sup> | BCAM                | 124                      | 14                | 9.47E-04                      |
| MNS                       | М               | GYPA, GYPB,<br>GYPC | 688                      | 132               | 6.80E-03                      |
| MNS                       | Ν               | GYPA, GYPB,<br>GYPC | 688                      | 214               | 1.18E-02                      |
| MNS                       | S               | GYPA, GYPB,<br>GYPC | 688                      | 44                | 1.54E-05                      |
| MNS                       | S               | GYPA, GYPB,<br>GYPC | 688                      | 49                | 1.19E-04                      |
| Р1РК                      | P1              | A4GALT,<br>B3GALNT1 | 368                      | 135               | 1.73E-02                      |
| Rh                        | С               | RHCE, RHD           | 266                      | 108               | 9.23E-03                      |
| Rh                        | С               | RHCE, RHD           | 266                      | 68                | 3.23E-03                      |
| Rh                        | Cw              | RHCE, RHD           | 266                      | 53                | 2.80E-03                      |
| Rh                        | C×              | RHCE, RHD           | 266                      | 12                | 4.70E-03                      |
| Rh                        | D               | RHCE, RHD           | 266                      | 113               | 7.47E-03                      |
| Rh                        | E               | RHCE, RHD           | 266                      | 80                | 1.07E-03                      |
| Rh                        | е               | RHCE, RHD           | 266                      | 23                | 1.33E-03                      |
| Rh                        | hr <sup>B</sup> | RHCE, RHD           | 266                      | 20                | 1.39E-03                      |
| Rh                        | hrs             | RHCE, RHD           | 266                      | 22                | 7.71E-03                      |

# Table 2. Characteristics of the Finnish classification models.

 $^{a}$  O, A<sub>1</sub>, and A<sub>2</sub> and in this column refer to phenotype.

<sup>b</sup> Misclassification frequency obtained from out-of-bag data.

| Blood group/HPA<br>system | Antigen <sup>a</sup> | Sensitivity | Specificity | Positive<br>predictive value | Negative<br>predictive value | Balanced accuracy |
|---------------------------|----------------------|-------------|-------------|------------------------------|------------------------------|-------------------|
| ABO                       | А                    | 0.997       | 1.000       | 1.000                        | 0.996                        | 0.999             |
| ABO                       | A <sub>1</sub>       | 1.000       | 1.000       | 1.000                        | 1.000                        | 1.000             |
| ABO                       | A <sub>2</sub>       | 1.000       | 1.000       | 1.000                        | 1.000                        | 1.000             |
| ABO                       | AB                   | 1.000       | 1.000       | 1.000                        | 1.000                        | 1.000             |
| ABO                       | В                    | 1.000       | 1.000       | 1.000                        | 1.000                        | 1.000             |
| ABO                       | 0                    | 1.000       | 0.996       | 0.997                        | 1.000                        | 0.998             |
| Cartwright                | Yt <sup>b</sup>      | 1.000       | 1.000       | 1.000                        | 1.000                        | 1.000             |
| Colton                    | Co <sup>a</sup>      | 1.000       | 1.000       | 1.000                        | 1.000                        | 1.000             |
| Colton                    | Co <sup>b</sup>      | 1.000       | 0.952       | 0.996                        | 1.000                        | 0.976             |
| Dombrock                  | Do <sup>a</sup>      | 1.000       | 1.000       | 1.000                        | 1.000                        | 1.000             |
| Dombrock                  | Dob                  | 1.000       | 1.000       | 1.000                        | 1.000                        | 1.000             |
| Duffy                     | Fy <sup>a</sup>      | 1.000       | 1.000       | 1.000                        | 1.000                        | 1.000             |
| Duffy                     | Fy <sup>b</sup>      | 0.979       | 1.000       | 1.000                        | 0.993                        | 0.990             |
| Gerbich                   | Ls <sup>a</sup>      | 1.000       | 0.667       | 0.989                        | 1.000                        | 0.833             |
| HPA-1                     | HPA-1a               | 0.900       | 1.000       | 1.000                        | 0.991                        | 0.950             |
| HPA-1                     | HPA-1b               | 1.000       | 1.000       | 1.000                        | 1.000                        | 1.000             |
| Kell                      | К                    | 1.000       | 1.000       | 1.000                        | 1.000                        | 1.000             |
| Kell                      | Kpa                  | 1.000       | 1.000       | 1.000                        | 1.000                        | 1.000             |
| Kell                      | Ula                  | 1.000       | 1.000       | 1.000                        | 1.000                        | 1.000             |
| Kidd                      | Jka                  | 1.000       | 1.000       | 1.000                        | 1.000                        | 1.000             |
| Kidd                      | Jkp                  | 0.995       | 1.000       | 1.000                        | 0.998                        | 0.997             |
| Landsteiner-Wiener        | LW <sup>b</sup>      | 0.994       | 1.000       | 1.000                        | 0.889                        | 0.997             |
| Lewis                     | Le <sup>a</sup>      | 0.991       | 1.000       | 1.000                        | 0.929                        | 0.996             |
| Lewis                     | Le <sup>b</sup>      | 0.880       | 1.000       | 1.000                        | 0.971                        | 0.940             |
| Lutheran                  | Lu <sup>a</sup>      | 1.000       | 1.000       | 1.000                        | 1.000                        | 1.000             |
| MNS                       | М                    | 0.972       | 0.994       | 0.959                        | 0.996                        | 0.983             |
| MNS                       | Ν                    | 0.992       | 0.986       | 0.980                        | 0.994                        | 0.989             |
| MNS                       | S                    | 1.000       | 1.000       | 1.000                        | 1.000                        | 1.000             |
| MNS                       | S                    | 1.000       | 1.000       | 1.000                        | 1.000                        | 1.000             |
| Р1РК                      | P1                   | 1.000       | 0.979       | 0.938                        | 1.000                        | 0.990             |
| Rh                        | С                    | 0.978       | 1.000       | 1.000                        | 0.982                        | 0.989             |
| Rh                        | с                    | 1.000       | 0.994       | 0.976                        | 1.000                        | 0.997             |
| Rh                        | Cw                   | 0.996       | 1.000       | 1.000                        | 0.905                        | 0.998             |
| Rh                        | C×                   | 0.986       | 1.000       | 1.000                        | 0.909                        | 0.993             |
| Rh                        | D                    | 0.970       | 0.993       | 0.982                        | 0.988                        | 0.982             |
| Rh                        | Е                    | 1.000       | 0.975       | 0.994                        | 1.000                        | 0.987             |
| Rh                        | е                    | 1.000       | 0.998       | 0.957                        | 1.000                        | 0.999             |
| Rh                        | hr <sup>B</sup>      | 1.000       | 0.998       | 0.955                        | 1.000                        | 0.999             |
| Rh                        | hr <sup>s</sup>      | 0 933       | 0 986       | 0.636                        | 0 998                        | 0.960             |

# Table 3. Accuracy metrics for the Finnish models in the Finnish test data set.

<sup>a</sup> O,  $A_1$ , and  $A_2$  and in this column refer to phenotype.

| Blood group/HPA<br>system | Antigenª        | Sensitivity | Specificity | Positive<br>predictive<br>value | Negative<br>predictive<br>value | Balanced accuracy |
|---------------------------|-----------------|-------------|-------------|---------------------------------|---------------------------------|-------------------|
| ABO                       | А               | 0.999       | 0.998       | 0.998                           | 0.999                           | 0.998             |
| ABO                       | A1              | 0.971       | 0.992       | 0.974                           | 0.991                           | 0.981             |
| ABO                       | A <sub>2</sub>  | 0.975       | 0.810       | 0.933                           | 0.922                           | 0.893             |
| ABO                       | AB              | 1.000       | 0.996       | 1.000                           | 0.997                           | 0.998             |
| ABO                       | В               | 1.000       | 0.998       | 1.000                           | 0.998                           | 0.999             |
| ABO                       | 0               | 0.999       | 0.997       | 0.998                           | 0.999                           | 0.998             |
| Cartwright                | Yt <sup>a</sup> | 1.000       | 1.000       | 0.933                           | 1.000                           | 1.000             |
| Cartwright                | Yt <sup>b</sup> | 0.999       | 1.000       | 1.000                           | 0.985                           | 0.999             |
| Colton                    | Coa             | 0.500       | 1.000       | 0.750                           | 0.999                           | 0.750             |
| Colton                    | Co <sup>b</sup> | 0.993       | 0.950       | 0.995                           | 0.928                           | 0.971             |
| Dombrock                  | Do <sup>a</sup> | 1.000       | 0.999       | 0.999                           | 1.000                           | 1.000             |
| Dombrock                  | Do <sup>b</sup> | 0.996       | 1.000       | 0.998                           | 0.999                           | 0.998             |
| Duffy                     | Fy <sup>a</sup> | 0.995       | 0.998       | 0.996                           | 0.998                           | 0.997             |
| Duffy                     | Fy <sup>b</sup> | 0.963       | 0.999       | 0.995                           | 0.991                           | 0.981             |
| HPA-1                     | HPA-1a          | 1.000       | 1.000       | 1.000                           | 1.000                           | 1.000             |
| HPA-1                     | HPA-1b          | 0.994       | 1.000       | 1.000                           | 0.988                           | 0.997             |
| Kell                      | К               | 0.996       | 0.906       | 0.992                           | 0.956                           | 0.951             |
| Kell                      | k               | 0.681       | 1.000       | 0.942                           | 0.997                           | 0.840             |
| Kell                      | Kpa             | 0.999       | 0.888       | 0.997                           | 0.956                           | 0.944             |
| Kell                      | Кр <sup>ь</sup> | 0.400       | 1.000       | 1.000                           | 0.999                           | 0.700             |
| Kidd                      | Jka             | 0.996       | 0.998       | 0.995                           | 0.999                           | 0.997             |
| Kidd                      | Jk <sup>b</sup> | 0.996       | 0.999       | 0.997                           | 0.998                           | 0.997             |
| Knops                     | Knª             | 0.000       | 1.000       | NA                              | 0.999                           | 0.500             |
| Knops                     | Kn <sup>b</sup> | 1.000       | 1.000       | 1.000                           | 1.000                           | 1.000             |
| Lewis                     | Le <sup>a</sup> | 0.996       | 0.986       | 0.997                           | 0.981                           | 0.991             |
| Lewis                     | Le <sup>b</sup> | 0.499       | 0.979       | 0.948                           | 0.717                           | 0.739             |
| Lutheran                  | Lu <sup>a</sup> | 0.997       | 0.931       | 0.994                           | 0.971                           | 0.964             |
| Lutheran                  | Lu <sup>b</sup> | 0.750       | 1.000       | 0.923                           | 0.999                           | 0.875             |
| MNS                       | Μ               | 0.989       | 0.998       | 0.993                           | 0.997                           | 0.994             |
| MNS                       | Ν               | 0.981       | 0.990       | 0.975                           | 0.993                           | 0.986             |
| MNS                       | S               | 0.997       | 0.997       | 0.997                           | 0.997                           | 0.997             |
| MNS                       | S               | 0.985       | 0.999       | 0.995                           | 0.998                           | 0.992             |
| P1PK                      | P1              | 0.939       | 0.996       | 0.986                           | 0.982                           | 0.968             |
| Rh                        | С               | 0.994       | 0.999       | 0.999                           | 0.997                           | 0.997             |
| Rh                        | С               | 0.997       | 0.999       | 0.995                           | 0.999                           | 0.998             |
| Rh                        | Cw              | 0.998       | 0.898       | 0.997                           | 0.952                           | 0.948             |
| Rh                        | D               | 0.994       | 0.999       | 0.997                           | 0.998                           | 0.997             |
| Rh                        | E               | 0.999       | 0.989       | 0.996                           | 0.998                           | 0.994             |
| Rh                        | е               | 0.962       | 1.000       | 0.993                           | 0.999                           | 0.981             |
| Vel                       | Vel             | 0.568       | 1.000       | 0.955                           | 0.999                           | 0.784             |

# Table 4. Accuracy metrics for the Danish models in the Danish test data set.

<sup>a</sup> O, A<sub>1</sub>, and A<sub>2</sub> and in this column refer to phenotype.

|                        |                      | Balanced accuracy                       |  |                                       |  |  |
|------------------------|----------------------|---|--|---------------------------------------|--|--|
| Blood group/HPA system | Antigen <sup>a</sup> | Finnish full data set<br>Finnish models | Danish full data set<br>Finnish models | Danish full data set<br>Danish models |  |  |
| ABO                    | А                    | 0.999                                   | 0.995                                  | 0.999                                 |  |  |
| ABO                    | A <sub>1</sub>       | 1.000                                   | 0.980                                  | 0.984                                 |  |  |
| ABO                    | A <sub>2</sub>       | 0.981                                   | 0.894                                  | 0.891                                 |  |  |
| ABO                    | AB                   | 1.000                                   | 0.998                                  | 0.999                                 |  |  |
| ABO                    | В                    | 1.000                                   | 0.987                                  | 0.999                                 |  |  |
| ABO                    | 0                    | 0.999                                   | 0.995                                  | 0.998                                 |  |  |
| Cartwright             | Yt <sup>a</sup>      | NA                                      | NA                                     | 1.000                                 |  |  |
| Cartwright             | Yt <sup>b</sup>      | 1.000                                   | 0.998                                  | 0.998                                 |  |  |
| Colton                 | Co <sup>a</sup>      | 1.000                                   | 0.833                                  | 0.833                                 |  |  |
| Colton                 | Co <sup>b</sup>      | 0.988                                   | 0.926                                  | 0.963                                 |  |  |
| Dombrock               | Doa                  | 1.000                                   | 0.999                                  | 0.999                                 |  |  |
| Dombrock               | Do <sup>b</sup>      | 1.000                                   | 0.999                                  | 0.999                                 |  |  |
| Duffy                  | Fy <sup>a</sup>      | 1.000                                   | 0.979                                  | 0.997                                 |  |  |
| Duffy                  | Fy <sup>b</sup>      | 0.993                                   | 0.971                                  | 0.980                                 |  |  |
| Gerbich                | Ls <sup>a</sup>      | 0.917                                   | NA                                     | NA                                    |  |  |
| HPA-1                  | HPA-1a               | 1.000                                   | 1.000                                  | 1.000                                 |  |  |
| HPA-1                  | HPA-1b               | 0.986                                   | 0.939                                  | 0.999                                 |  |  |
| Kell                   | К                    | 1.000                                   | 0.916                                  | 0.956                                 |  |  |
| Kell                   | k                    | NA                                      | NA                                     | 0.838                                 |  |  |
| Kell                   | Kpa                  | 1.000                                   | 0.935                                  | 0.961                                 |  |  |
| Kell                   | Кр <sup>ь</sup>      | NA                                      | NA                                     | 0.750                                 |  |  |
| Kell                   | Ulª                  | 1.000                                   | NA                                     | NA                                    |  |  |
| Kidd                   | Jka                  | 1.000                                   | 0.995                                  | 0.997                                 |  |  |
| Kidd                   | Jk <sup>b</sup>      | 0.999                                   | 0.662                                  | 0.997                                 |  |  |
| Knops                  | Kna                  | NA                                      | NA                                     | 0.750                                 |  |  |
| Knops                  | Kn <sup>b</sup>      | NA                                      | NA                                     | 1.000                                 |  |  |
| Landsteiner Wiener     | LW <sup>b</sup>      | 0.998                                   | 0.500                                  | NA                                    |  |  |
| Lewis                  | Le <sup>a</sup>      | 0.998                                   | 0.981                                  | 0.989                                 |  |  |
| Lewis                  | Le <sup>b</sup>      | 0.968                                   | 0.729                                  | 0.736                                 |  |  |
| Lutheran               | Lu <sup>a</sup>      | 0.988                                   | 0.956                                  | 0.964                                 |  |  |
| Lutheran               | Lup                  | NA                                      | NA                                     | 0.828                                 |  |  |
| MNS                    | M                    | 0.984                                   | 0.970                                  | 0.993                                 |  |  |
| MNS                    | N                    | 0.988                                   | 0.947                                  | 0.987                                 |  |  |
| MNS                    | S                    | 1 000                                   | 0.995                                  | 0.997                                 |  |  |
| MNS                    | S                    | 1 000                                   | 0.988                                  | 0.993                                 |  |  |
| P1PK                   | P1                   | 0.984                                   | 0.500                                  | 0.965                                 |  |  |
| Rh                     | C C                  | 0.989                                   | 0.646                                  | 0.997                                 |  |  |
| Bh                     | C<br>C               | 0.997                                   | 0.500                                  | 0.997                                 |  |  |
| Rh                     | C <sup>w</sup>       | 0.999                                   | 0.918                                  | 0.953                                 |  |  |
| Rh                     | C×                   | 0.995                                   | NΔ                                     | ΝΔ                                    |  |  |
| Rh                     | n                    | 0.988                                   | 0 78/                                  | 0 007                                 |  |  |
| Rh                     | F                    | 0.900                                   | 0.704                                  | 0.397                                 |  |  |
| Dh                     | L                    | 0.990                                   | 0.332                                  | 0.995                                 |  |  |
| Dh                     | с<br>hr <sup>B</sup> | 0.300                                   | U.302<br>NIA                           | U.304<br>NIA                          |  |  |
| Rh                     | III-<br>hrS          | 0.300                                   | NA<br>NA                               | NA<br>NA                              |  |  |
|                        |                      | 0.322                                   |  | NA<br>0 911                           |  |  |
| Vel                    | Vel                  | NA                                      | NA                                     | 0.811                                 |  |  |

NA, data not available.

 $^{a}$  O, A1, and A2 and in this column refer to phenotype.





Figure 1. Study design.



Figure 2. Confusion matrices of the Finnish models in the Finnish test data set.



Figure 3. Posterior probability boxplots of the Finnish models in the Finnish test data set.